|Expense Ratio (net)||N/A|
|Last Cap Gain||N/A|
|Morningstar Risk Rating||N/A|
|Beta (3Y Monthly)||N/A|
|5y Average Return||N/A|
|Average for Category||N/A|
LAVAL, Quebec, Oct. 10, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the 2019 Aspire Higher scholarship program recipients. The program, which since 2013 has granted more than $648,000 in scholarships to students who have been affected by dermatologic conditions, will award nine students with scholarships of $10,000 each to pursue their undergraduate or graduate degrees.
LAVAL, Quebec , July 8, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its second-quarter 2019 financial results on Tuesday, Aug. 6, 2019 . Bausch ...
Moody's Investors Service ("Moody's") assigned a Ba2 rating to the new senior secured note offering of Bausch Health Companies Inc. ("Bausch Health"), and a B3 rating to the new senior unsecured note offering of Bausch Health Americas, Inc. (formerly known as Valeant Pharmaceuticals International), guaranteed by Bausch Health. There are no changes to Bausch Health's other ratings including the B2 Corporate Family Rating, the B2-PD Probability of Default Rating, the Ba2 senior secured rating, B3 senior unsecured rating and SGL-1 Speculative Grade Liquidity Rating. The transaction is credit positive because it will extend Bausch Health's debt maturities.
Heading into December, biotech stocks held up fairly well in 2018. Evaluate Pharma , a firm specializing in data-driven news and analysis in biotech, compiled a list of blockbuster drugs in the works with ...
BRIDGEWATER, N.J., Dec. 5, 2018 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lenses, the first multifocal toric lens to be available as a standard offering in the eye care professional's fit set. "Eye care professionals have routinely stressed the need to have a readily available contact lens that addresses both presbyopia and astigmatism, underscoring the critical vision needs of this growing patient population," said Joe Gordon, U.S. president, Bausch + Lomb.
Moody's Investors Service ("Moody's") upgraded the ratings of Bausch Health Companies Inc. ("Bausch Health") including the Corporate Family Rating to B2 from B3, the Probability of Default Rating to B2-PD from B3-PD, the senior secured rating to Ba2 from Ba3 and the senior unsecured rating to B3 from Caa1. "The upgrade reflects continued progress in Bausch Health's turnaround including organic growth in major business lines, resolution of the Xifaxan patent challenge, and Moody's expectation for continued debt reduction," stated Michael Levesque, Moody's Senior Vice President.
LAVAL, Quebec, Oct. 30, 2018 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the U.S. launch of ALTRENOTM (tretinoin) Lotion, 0.05% for the topical treatment of acne vulgaris in patients 9 years of age and older. ALTRENO Lotion is the first and only tretinoin available in a lotion for acne.